Ambroxol Hydrochloride Syrup

This product has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thereby significantly promoting expectoration and improving respiratory conditions. When treated with this product, the patient's mucus secretion can return to normal. Cough and sputum volume are usually significantly reduced, and the surfactant of the respiratory mucosa can thus play its normal protective function. Since this drug has good tolerance, it can be used for a long time. The toxicity index of ambroxol in acute toxicity tests is very low. Ambroxol is not mutagenic (Ames and micronucleus tests). Carcinogenicity studies on mice and rats have shown that ambroxol is not carcinogenic.

trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride

Colorless clear or almost clear liquid

It is suitable for acute and chronic respiratory diseases accompanied by abnormal sputum secretion and poor expectoration function, such as: acute exacerbation of chronic bronchitis, asthmatic bronchitis, and expectorant treatment of bronchial asthma.

Adults and children over 12 years old: 10 ml (2 tablespoons) each time, twice a day. Children under 12 years old are recommended to use the following treatment doses according to their condition: Children aged 6-12 years old: 5 ml (1 tablespoon) each time, 2-3 times a day. Children aged 2-6 years old: 2.5 ml (1/2 tablespoon) each time, 3 times a day. Children aged 1-2 years old: 2.5 ml (1/2 tablespoon) each time, 2 times a day. This dosage is appropriate for the treatment of acute respiratory diseases and the initial treatment of chronic diseases. The dose can be halved after 14 days. This product is best taken at mealtime.

This product is generally well tolerated. Mild upper gastrointestinal adverse reactions have been reported (mainly heartburn, indigestion and occasional nausea and vomiting). Allergic reactions are rare, mainly rashes. Severe acute allergic reactions have been reported in rare cases, but their relevance to ambroxol hydrochloride is uncertain, and some of these patients are usually allergic to other substances.

It should not be used by patients with known hypersensitivity to ambroxol hydrochloride or other ingredients of the formula.

The combined use of this product with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) can increase the concentration of antibiotics in lung tissue. There are no reports of clinically relevant adverse interactions with other drugs.

Store in a sealed container at 30°C in a dark place. Keep out of reach of children!

100 ml: 0.6 g